Clinical trials: Virus Diseases
Respiratory Syncytial Virus Infections
A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
The purpose of this long-term follow-up (LTFU) study is to evaluate the incidence of the clinical diagnosis of asthma and the frequency of wheezing in infants and children with respiratory syncytial virus (RSV) infection who were…
- Trial name
- NCT03332459
- Testing
- Lumicitabine
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19 Infection
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Treatment of patients hospitalised for management of moderate COVID-19 infection
- Trial name
- Neptuno (NCT04784559)
- Testing
- Plitidepsin, Dexamethasone, Remdesivir
- Where
- 28 sites in Brazil, Bulgaria and 6 more
- Volunteers
- 205 people
- Sponsor
- PharmaMar
Influenza, Human
Intramuscular CodaVax-H1N1 in Healthy Adults
This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years.
- Trial name
- NCT05223179
- Testing
- CODA-VAX H1N1, Flucelvax Quad, Saline
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Influenza
Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.
The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a more immunogenic and effective response compared with conventional influenza vaccines in elderly and adults.
- Trial name
- NCT02255279
- Testing
- Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29), Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).
- Where
- 3 sites in Mexico
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Condylomata Acuminata
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts
This trial will be a phase 2, open-label, study to evaluate the safety, tolerability, and efficacy of VIR007 when administered topically for up to 60 days to adults between the ages of 18 to 65 years with a clinical diagnosis of…
- Trial name
- NCT03158974
- Testing
- East Indian Sandalwood Oil Cream
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ViroXis Corporation
Hepatitis C, Chronic
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
The purpose of this study is to evaluate the efficacy (proportion of subjects with SVR12), safety, tolerability and pharmacokinetics of an 8- and 6-week treatment regimen of AL-335, odalasvir (ODV) and simeprevir (SMV) in chronic…
- Trial name
- NCT02765490
- Testing
- AL-335, Odalasvir, Simeprevir
- Where
- 28 sites in Belgium, Canada and 4 more
- Volunteers
- 365 people
- Sponsor
- Janssen Research & Development, LLC
Influenza, Human
The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
The purpose of this study is to evaluate the safety, tolerance, and immunogenicity of MAS-1-Adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted…
- Trial name
- MER4101 (NCT02500680)
- Testing
- MER4101, Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Nova Immunotherapeutics Limited
Hepatitis C
Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies
The objective of this observational study is to characterize long-term (5 years post event) clinical outcomes in patients who experienced a thromboembolic event (TEE) during participation in the GSK ENABLE clinical trials.
- Trial name
- NCT01715779
- Testing
- Eltrombopag
- Volunteers
- 22 people
- Sponsor
- Novartis
Chronic Hepatitis B
Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
The objective of this 96-week study was to evaluate the safety and antiviral efficacy of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, coformulated; Truvada®) with or without hepatitis B immunoglobulin (HBIg) in…
- Trial name
- NCT00507689
- Testing
- FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
COVID-19
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone…
- Trial name
- NCT04347174
- Testing
- Suspension of heat killed (autoclaved) Mycobacterium w
- Where
- 4 sites in India
- Volunteers
- 40 people
- Sponsor
- Cadila Pharnmaceuticals
Covid-19, Sars-CoV2
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus…
- Conditions
- Covid-19, Sars-CoV2, Diabete Mellitus, Cardiopathy
- Trial name
- NCT04407182
- Testing
- Viusid and Asbrip
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2…
- Trial name
- NCT04359680
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 26 sites in United States
- Volunteers
- 1,407 people
- Sponsor
- Romark Laboratories L.C.
COVID-19
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
- Trial name
- NCT04591717
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
SARS-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04487574
- Testing
- XC221
- Where
- 5 sites in Russia
- Volunteers
- 118 people
- Sponsor
- RSV Therapeutics LLC
COVID-19
Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms.
- Trial name
- NCT05216497
- Testing
- Ingavirin®, 90 mg capsules
- Where
- 14 sites in Russia
- Volunteers
- 233 people
- Sponsor
- Valenta Pharm JSC
COVID-19, Pneumonia
A Study of LY3127804 in Participants With COVID-19
A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.
- Trial name
- NCT04342897
- Testing
- LY3127804
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria, Tetanus
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years
The study objective is to assess the immunogenicity and safety of DTaP-IPV combination vaccine administered as a boosting dose to healthy 4 to 6-year-old children who received three doses of primary immunization against…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- Aladdin (NCT04618640)
- Testing
- DTaP-IPV combination vaccine
- Where
- 26 sites in South Korea
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Boryung Biopharma Co., Ltd.
Fatigue Syndrome, Chronic, Cold
Effectiveness of Antrodia Cinnamomea Mycelia on Improving Immune Response in Subhealth People
This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people.
- Trial name
- NCT05728918
- Testing
- Antrodia cinnamomea mycelia
- Where
- Taiwan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Greenyn Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.